These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17227689)

  • 1. Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV).
    Vogel LN; Roberts A; Paddock CD; Genrich GL; Lamirande EW; Kapadia SU; Rose JK; Zaki SR; Subbarao K
    Vaccine; 2007 Mar; 25(12):2173-9. PubMed ID: 17227689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.
    Fett C; DeDiego ML; Regla-Nava JA; Enjuanes L; Perlman S
    J Virol; 2013 Jun; 87(12):6551-9. PubMed ID: 23576515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.
    Iwata-Yoshikawa N; Uda A; Suzuki T; Tsunetsugu-Yokota Y; Sato Y; Morikawa S; Tashiro M; Sata T; Hasegawa H; Nagata N
    J Virol; 2014 Aug; 88(15):8597-614. PubMed ID: 24850731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
    Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
    Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.
    Tseng CT; Sbrana E; Iwata-Yoshikawa N; Newman PC; Garron T; Atmar RL; Peters CJ; Couch RB
    PLoS One; 2012; 7(4):e35421. PubMed ID: 22536382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
    Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
    Microbiol Immunol; 2009 Feb; 53(2):75-82. PubMed ID: 19291090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
    Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N
    J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.
    Sui J; Li W; Roberts A; Matthews LJ; Murakami A; Vogel L; Wong SK; Subbarao K; Farzan M; Marasco WA
    J Virol; 2005 May; 79(10):5900-6. PubMed ID: 15857975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
    See RH; Zakhartchouk AN; Petric M; Lawrence DJ; Mok CPY; Hogan RJ; Rowe T; Zitzow LA; Karunakaran KP; Hitt MM; Graham FL; Prevec L; Mahony JB; Sharon C; Auperin TC; Rini JM; Tingle AJ; Scheifele DW; Skowronski DM; Patrick DM; Voss TG; Babiuk LA; Gauldie J; Roper RL; Brunham RC; Finlay BB
    J Gen Virol; 2006 Mar; 87(Pt 3):641-650. PubMed ID: 16476986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.
    Lu B; Huang Y; Huang L; Li B; Zheng Z; Chen Z; Chen J; Hu Q; Wang H
    Immunology; 2010 Jun; 130(2):254-61. PubMed ID: 20406307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.
    Hu H; Lu X; Tao L; Bai B; Zhang Z; Chen Y; Zheng F; Chen J; Chen Z; Wang H
    Clin Vaccine Immunol; 2007 Jul; 14(7):894-901. PubMed ID: 17494640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.
    Roberts A; Lamirande EW; Vogel L; Baras B; Goossens G; Knott I; Chen J; Ward JM; Vassilev V; Subbarao K
    Viral Immunol; 2010 Oct; 23(5):509-19. PubMed ID: 20883165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
    Rockx B; Corti D; Donaldson E; Sheahan T; Stadler K; Lanzavecchia A; Baric R
    J Virol; 2008 Apr; 82(7):3220-35. PubMed ID: 18199635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.
    Sheahan T; Whitmore A; Long K; Ferris M; Rockx B; Funkhouser W; Donaldson E; Gralinski L; Collier M; Heise M; Davis N; Johnston R; Baric RS
    J Virol; 2011 Jan; 85(1):217-30. PubMed ID: 20980507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.
    Liu YV; Massare MJ; Barnard DL; Kort T; Nathan M; Wang L; Smith G
    Vaccine; 2011 Sep; 29(38):6606-13. PubMed ID: 21762752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice.
    Subbarao K; McAuliffe J; Vogel L; Fahle G; Fischer S; Tatti K; Packard M; Shieh WJ; Zaki S; Murphy B
    J Virol; 2004 Apr; 78(7):3572-7. PubMed ID: 15016880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV.
    Gai WW; Zhang Y; Zhou DH; Chen YQ; Yang JY; Yan HM
    Virol Sin; 2011 Apr; 26(2):81-94. PubMed ID: 21468931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
    Spruth M; Kistner O; Savidis-Dacho H; Hitter E; Crowe B; Gerencer M; Brühl P; Grillberger L; Reiter M; Tauer C; Mundt W; Barrett PN
    Vaccine; 2006 Jan; 24(5):652-61. PubMed ID: 16214268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice.
    Yang ZY; Kong WP; Huang Y; Roberts A; Murphy BR; Subbarao K; Nabel GJ
    Nature; 2004 Apr; 428(6982):561-4. PubMed ID: 15024391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterologous viral RNA export elements improve expression of severe acute respiratory syndrome (SARS) coronavirus spike protein and protective efficacy of DNA vaccines against SARS.
    Callendret B; Lorin V; Charneau P; Marianneau P; Contamin H; Betton JM; van der Werf S; Escriou N
    Virology; 2007 Jul; 363(2):288-302. PubMed ID: 17331558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.